Antiseizure

Carbamazepine and oxcarbazepine

Two HLA alleles, two different reactions, and recommendations that name populations rather than applying to everybody. The population part is not a footnote on the guidance — it is the guidance.

What this drug connects to

The genes involved

HLA-B

Drug-Induced Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis →

HLA-B*15:02 is strongly associated with a greater risk of Stevens–Johnson syndrome and toxic epidermal necrolysis in people treated with carbamazepine or oxcarbazepine. A separate allele, HLA-A*31:01, is associated with a greater risk of maculopapular exanthema, DRESS and SJS/TEN with carbamazepine. CPIC issued recommendations for the use of both drugs based on HLA genotype in its 2017 update. Allele frequencies differ substantially between populations, and this is a test ordered by a prescriber before a first dose — not something to act on from a consumer raw data file.

CPIC Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (Clin Pharmacol Ther 2018, PMID 29392710).

Variants MyGeneLog reports for these genes

These are the positions in your own file that carry the genes above. Not every gene in a guideline is one we report — where that is the case the gene appears above without a variant here, and the note says so.

Crohn's disease

HLA-B · rs114985235

HIV-1 control

HLA-B · rs2523590

HIV-1 control

HLA-B · rs2395029

This page is educational and contains no dosing information. Where a clinical guideline covers one of these gene-drug pairs it is written for prescribers and works through validated algorithms alongside clinical monitoring. Nothing here is a reason to start, stop, or change a medication — that conversation belongs with the clinician or pharmacist managing your treatment.